Issues
-
Cover Image
Cover Image
FGFR3 and PIK3CA mutations are common in bladder cancer (BC) but the etiologies of these driver mutations are not well known. The research article by Rao and colleagues, starting on page 561, explored the associations between several BC risk factors and specific mutations in these driver genes. Polyomavirus infection has been previously linked to increased BC risk in immunocompromised organ transplant recipients. The cover image shows immunohistological (IHC) staining against polyomavirus Large T-antigen (brown dots) in tissue microarrays of tumors with FGFR3 and/or PIK3CA mutations from a population-based study of BC patients. This isolated and sparse Large T-antigen staining pattern observed in this study suggests the involvement of polyomavirus infection and differs from the strong staining seen in organ transplant recipients who develop muscle-invasive BC. In the current study, polyomavirus positivity was more likely to be detected by RNAseq and IHC staining in non-muscle invasive tumors with APOBEC-type mutations in the FGFR3 or PIK3CA genes, suggesting a viral etiology for these mutations in a subset of BC. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Highlights from the Literature
Perspective
Spotlight
Review
Research Articles
Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
Tobacco smoking likely causes one of the most common mutations in bladder tumors (FGFR3-Y375C), while viral infections might contribute to three others (FGFR3-S249C, PIK3CA-E542K, and PIK3CA-E545K). Understanding the causes of these mutations may lead to new prevention and treatment strategies, such as viral screening and vaccination.
Psychosocial Risk Profiles and Colorectal Cancer Screening: A Latent Profile Analysis in a Colorectal Cancer Screening Intervention Setting
This LPA analysis provides some direction for tailoring colorectal cancer educational interventions to improve the benefits and barriers among individuals with high susceptibility scores in hard-to-screen populations such as our border population.
Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study
This mixed-methods study is the first to investigate and assess barriers and opportunities for HPV vaccine delivery among PAYA cancer healthcare providers. Our findings can serve as an important framework for future implementation research targeted towards HPV vaccine delivery in cancer clinical settings.
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.